Juvenile idiopathic arthritis: Therapies in the 21st century

Bulletin of the NYU Hospital for Joint Diseases

Volumn 65, Issue 3, 2007, Pages 205-211

  Haines, Kathleen A ^a,b,c,d  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^d Department of Pediatrics ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIINFLAMMATORY AGENT; ATLIZUMAB; CELECOXIB; CORTICOSTEROID; ETANERCEPT; GADOLINIUM; GOLD COMPLEX; HYDROXYCHLOROQUINE; IBUPROFEN; INDOMETACIN; INFLIXIMAB; MELOXICAM; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PENICILLAMINE; PLACEBO; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ROFECOXIB; TOLMETIN; TRIAMCINOLONE HEXACETONIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ARTHRITIS; CLINICAL TRIAL; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HEALTH SURVEY; HUMAN; IMMUNE SYSTEM; JUVENILE RHEUMATOID ARTHRITIS; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UVEITIS; CHILD; CLASSIFICATION; IMMUNOLOGY;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; METHOTREXATE; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 38449093582     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004 Feb;31(2):390-2.
2. Foeldvari I, Bidde M. Validation of the proposed ILAR classification criteria for juvenile idiopathic arthritis. International League of Associations for Rheumatology. J Rheumatol. 2000 Apr;27(4):1069-72.
3. Wallace CA, Ravelli A, Huang B, Giannini EH. Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis. J Rheumatol. 2006 Apr;33(4):789-95.
4. Berntson L, Fasth A, Andersson-Gäre B, et al. The influence of heredity for psoriasis on the ILAR classification of juvenile idiopathic arthritis. J Rheumatol. 2002;29:2454-8.
5. Giannini EH, Cassidy JT, Brewer EJ, et al. Comparative efficacy and safety of advanced drug therapy in children with juvenile rheumatoid arthritis. Semin Arthritis Rheum. 1993 Aug;23(1):34-46.
6. Beukelman T, Guevara J, Albert DA, et al. Characterization of the treatment of juvenile idiopathic oligoarthritis by pediatric rheumatologists in the United States and Canada. Arthritis Rheum. 2006;54(Suppl):(Abstr).
7. Cron RQ, Sharma S, Sherry DD. Current treatment by United States and Canadian pediatric rheumatologists. J Rheumatol. 1999 Sep;26(9):2036-8.
8. Reiff A, Lovell DJ, Adelsberg JV, et al. Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension. J Rheumatol. 2006 May;33(5):985-95.
9. Foeldvari I, Szer I, Zemel LS, et al. Report of a 12-week study of celecoxib vs. naproxen in children with juvenile rheumatoid arthritis. Arthritis Rheum. 2006;54(Suppl):S684(Abstr).
10. Huppertz HI, Tschammler A, Horwitz AE, Schwab KO. Intraarticular corticosteroids for chronic arthritis in children: efficacy and effects on cartilage and growth. J Pediatr. 1995 Aug;127(2):317-21.
11. Sherry DD, Stein LD, Reed AM, et al. Prevention of leg length discrepancy in young children with pauciarticular juvenile rheumatoid arthritis by treatment with intraarticular steroids. Arthritis Rheum. 1999 Nov;42(11):2330-4.
12. Eberhard B, Gottlieb BS, Weiss JE, et al. Comparison of the intraarticular effectiveness of triamconolone hexacetonide to triamcinolone acetonide in juvenile rheumatoid arthritis. Arthritis Rheum. 2002;46(Suppl):S480(Abstr).
13. Gottlieb BS, Keenan GF, Lu T, Ilowite NT. Discontinuation of methotrexate treatment in juvenile rheumatoid arthritis. Pediatrics. 1997 Dec;100(6):994-7.
14. Giannini EH, Brewer EJ, Kuzmina N., et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med. 1992 Apr 16;326(16):1043-9.
15. Ruperto N, Murray KJ, Gerloni V, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 2004 Jul;50(7):2191-201.
16. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000 Mar 16;342(11):763-9.
17. Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997 Jul;40(7):1202-9(Abstr. )
18. Lovell DJ, Giannini EH, Reiff A, et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum. 2003 Jan;48(1):218-26.
19. Kimura Y, Pinho P, Walco G, et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2005 May;32(5):935-42.
20. Lahdenne P, VÃCurrency SignhÃCurrency Signsalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis. 2003 Mar;62(3):245-7.
21. Richards JC, Tay-Kearney ML, Murray K, Manners P. Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Experiment Ophthalmol. 2005 Oct;33(5):461-8
22. Rajaraman RT, Kimura Y, Li S, et al. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology. 2006 Feb;113(2):308-14.
23. Guignard S, Gossec L, Salliot C, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: A retrospective study. Ann Rheum Dis. 2006 Dec;65(12):1631-4.
24. Lovell DJ, Ruperto N, Jung L, et al. Long-term efficacy and safety of adalimumab in children with juvenile rheumatoid arthritis (JRA): 48-week results. Arthritis Rheum. 2006;54(Suppl.):S303.(Abstr).
25. Reiff A. The use of anakinra in juvenile arthritis. Curr Rheumatol Rep. 2005;7:434-40.
26. Pascual V, Allantaz F, Arce E, et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005 May 2;201(9):1479-86.
27. Woo P, Wilkinson N, Prieur AM, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther. 2005;7(6):R1281-8.
28. Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005 Mar;52(3):818-25.
29. Imagawa T, Mori M, Takei S, et al. Efficacy and safety of tocilizumab, an anti-Il-6 receptor monoclonal antibody, in patients with polyarticular or oligoarticular onset juvenile idiopathic arthritis. Arthritis Rheum. 2007;54(Suppl):(Abstr).
30. Lovell DJ, Ruperto N, Prieur AM, et al. Assessment of open label co-stimulation blockade with abatacept in children and adolescents with active juvenile idiopathic arthritis (JIA). Arthritis Rheum. 20006;54(Suppl.): S326(Abstr).
31. De Kleer IM, Brinkman DM, Ferster A, et al. Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality, and transplant related morbidity. Ann Rheum Dis. 2004 Oct;63(10):1318-26.
32. Wulffraat NM, Brinkman D, Ferster A, et al. Long-term follow-up of autologous stem cell transplantation for refractory juvenile idiopathic arthritis. Bone Marrow Transplant. 2003 Aug;32(Suppl 1):S61-4.
33. Wallace CA, Huang B, Bandeira M, et al. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum. 2005 Nov;52(11):3554-62.
34. Niehues T, Horneff G, Michels H, et al. Evidence-based use of methotrexate in children with rheumatic diseases: A consensus statement of the Working Groups Pediatric Rheumatology Germany (AGKJR) and Pediatric Rheumatology Austria. Rheumatol Int. 2005 Apr;25(3):169-78.